Cryosurgery during topical imiquimod: a successful combination modality for lentigo maligna
| dc.contributor.author | Bassukas, I. D. | en |
| dc.contributor.author | Gamvroulia, C. | en |
| dc.contributor.author | Zioga, A. | en |
| dc.contributor.author | Nomikos, K. | en |
| dc.contributor.author | Fotika, C. | en |
| dc.date.accessioned | 2015-11-24T19:26:10Z | |
| dc.date.available | 2015-11-24T19:26:10Z | |
| dc.identifier.issn | 1365-4632 | - |
| dc.identifier.uri | https://olympias.lib.uoi.gr/jspui/handle/123456789/22699 | |
| dc.rights | Default Licence | - |
| dc.subject | Adjuvants, Immunologic/*administration & dosage | en |
| dc.subject | Administration, Cutaneous | en |
| dc.subject | Aged | en |
| dc.subject | Aminoquinolines/*administration & dosage | en |
| dc.subject | Combined Modality Therapy | en |
| dc.subject | *Cryosurgery | en |
| dc.subject | Humans | en |
| dc.subject | Hutchinson's Melanotic Freckle/*therapy | en |
| dc.subject | Male | en |
| dc.subject | Skin Neoplasms/*therapy | en |
| dc.title | Cryosurgery during topical imiquimod: a successful combination modality for lentigo maligna | en |
| heal.abstract | BACKGROUND: Either cryosurgery or topical imiquimod have been used to treat patients with lentigo maligna in cases where surgery is not feasible. METHODS: We report a patient with lentigo maligna, who was treated with the combination of topical imiquimod and cryosurgery, and review the rationale, which led us to design the present combined cryo-immunological treatment modality. RESULTS: Sustained clearance of lentigo maligna to date (26 months after treatment). The successful treatment of this patient was based on the following rationale: A cryosurgery session during continuing imiquimod application may: (i) reinforce apoptosis of tumor cells; (ii) strengthen antiangiogenesis in the treated tumor; and (iii) build-up a potent tumor-destructive immune response by a cascade of events starting with imiquimod-promoted attraction of immature dendritic antigen-presenting cells (DCs) into the tumor. DCs further mature within the tumor-antigen-rich environment of subsequently cryo-destructed tumor and upon imiquimod-driven migration into the peripheral lymph nodes can stimulate a specific antineoplastic cell-mediated immunity. Finally, continuing imiquimod application after cryosurgery may increase recruitment of activated effector cells into the tumor tissue leading to its destruction. CONCLUSION: Cryosurgery during continued topical imiquimod seems to be a promising treatment for lentigo maligna. | en |
| heal.access | campus | - |
| heal.fullTextAvailability | TRUE | - |
| heal.identifier.primary | 10.1111/j.1365-4632.2008.03562.x | - |
| heal.identifier.secondary | http://www.ncbi.nlm.nih.gov/pubmed/18412875 | - |
| heal.identifier.secondary | http://onlinelibrary.wiley.com/store/10.1111/j.1365-4632.2008.03562.x/asset/j.1365-4632.2008.03562.x.pdf?v=1&t=h0oyore4&s=444775c337d4c4bcf39589144d89f782bfe7fc3b | - |
| heal.journalName | Int J Dermatol | en |
| heal.journalType | peer-reviewed | - |
| heal.language | en | - |
| heal.publicationDate | 2008 | - |
| heal.recordProvider | Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής | el |
| heal.type | journalArticle | - |
| heal.type.el | Άρθρο Περιοδικού | el |
| heal.type.en | Journal article | en |
Αρχεία
Φάκελος/Πακέτο αδειών
1 - 1 of 1
Φόρτωση...
- Ονομα:
- license.txt
- Μέγεθος:
- 1.74 KB
- Μορφότυπο:
- Item-specific license agreed upon to submission
- Περιγραφή: